Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kits Eyecare Ltd T.KITS

Alternate Symbol(s):  KTYCF

Kits Eyecare Ltd. is a Canada-based provider of vertically integrated and digitally native eyecare platforms. The Company operates through the sale of eyewear products to consumers. It offers customers access to a selection of contact lenses and eyeglasses, including its own KITS-designed products, as well as an advanced suite of online vision tools. Its collections include South Beach, Little Italy, Trail Blazer, KITS x Vasuma and Apres. The Company's designer glasses and sunglasses, including Alexander Mcqueen, Armourx, Betsey Johnson, Bottega Veneta, Calvin Klein Carrera, David Beckham, Diesel, Dior, Emilio Pucci, Emporio Armani, Gucci, Hugo Boss, Jimmy Choo, Judith Leiber, Kits, Persol, Prada, Ray-Ban, Superdry, Tom Ford, Under Armour, And Versace.


TSX:KITS - Post by User

Comment by nozzpackon Aug 30, 2022 4:41pm
93 Views
Post# 34930736

RE:Cannacords. $17 target ….Enroute To it ..2023

RE:Cannacords. $17 target ….Enroute To it ..2023Given the Green Shields exclusive eyecare deal, Green Shields planned and well executed growth plans to become Canada's largest healthcare company, Kits expanding service suite and the fact that it is not only disruptive but successfully so, with the huge US market waiting for its substantive entry, it's my view that Kits financial metrics will achieve Cannacords 2022 growth targets a year late.

That is , 2023 instead of Q 2022 .

Cannacords target of $17 per share will be achieved in 2023 , a year late but highly probable .
<< Previous
Bullboard Posts
Next >>